Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 1109

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 1109
---
 Incorporation is amended and restated to read in its entirety as follows:“A. This Company is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Company is authorized to issue is [] ([]) shares. [] ([]) shares shall be Common Stock, each having a par value of one-tenth of one cent ($0.001). Five million (5,000,000) shares shall be Preferred Stock, each having a par value of one-tenth of one cent ($0.001).”THIRD:The foregoing amendment to the Certificate of Incorporation was duly approved by the Board.FOURTH: Thereafter, pursuant to a resolution of the Board, this Certificate of Amendment was submitted to the stockholders of the Company for their approval, and was duly adopted in accordance with the provisions of Section 242 of the DGCL.[SIGNATURE PAGE FOLLOWS]​

#### G-1
IN WITNESS WHEREOF,Cara Therapeutics, Inc. has caused this Certificate of Amendment to be executed by its Chief Executive Officer as of [***DATE***].

| ​ | By: | ​                       |
| ​ | ​   | Christopher Posner      |
| ​ | ​   | Chief Executive Officer |

G-2

ANNEX H FORM OF PROXY CARD FOR SPECIAL MEETING OF CARA THERAPEUTICS, INC.

| Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V60671-TBD 1. Approve the issuance of shares of Cara common stock pursuant to the Merger, which (i) will represent more than 20% of the shares of Cara common stock outstanding immediately prior to the Merger and (ii) result in the change of control of Cara, pursuant to Rules 5635(a) and 5635(b) of Nasdaq, respectively, referred to as the Stock Issuance Proposal. 3. Approve the Tvardi Therapeutics, Inc. 2025 Employee Stock Purchase Plan, referred to as the ESPP Proposal. 2. Approve the Tvardi Therapeutics, Inc. 2025 Equity Incentive Plan